Claims for Patent: 8,389,215

Summary for Patent: 8,389,215

Title:	Non-invasive recovery of RNA and analysis of gene expression in skin
Abstract:	A liquid is placed on an area of skin in which an RNA sample is to be extracted. The liquid is configured to harden which allows for the hardened material to be peeled off. In some implementations, a substrate is attached to the liquid before it hardens to facilitate removal of the skin sample.
Inventor(s):	Krueger; Gerald (Salt Lake City, UT), Benson; Nicholas (San Diego, CA)
Assignee:	University of Utah Research Foundation (Salt Lake City, UT)
Application Number:	12/452,872
Patent Claims:	1. A method for isolating RNA molecules from a skin sample comprising: (a) applying a liquid to a skin surface; (b) applying a substrate to said liquid; (c) allowing said liquid to harden; (d) removing said substrate; (e) removing said skin sample from said hardened liquid; and (f) isolating RNA from said skin sample. 2. The method of claim 1, wherein the liquid is a sutureless wound closing agents. 3. The method of claim 1, wherein said substrate is selected from the group consisting of a glass slide, a spatula, a plastic film, cloth and plastic. 4. The method of claim 1, wherein said skin sample is collected from a location on a patient selected from the group consisting of the upper back, mastoid process, hand, foot and deltoid. 5. The method of claim 1, further comprising quantifying said RNA. 6. The method of claim 5, wherein said RNA is quantified for the relative levels of transcripts for GAPDH, TNF-.alpha., VEGF and K16. 7. The method of claim 4, wherein said locations include skin that is lesional and unaffected. 8. The method of claim 5, wherein said quantification is predictive of a patient's response to a drug. 9. The method of claim 8, wherein said patient has psoriasis and the drug is etanercept. 10. A method for isolating RNA molecules from a skin sample comprising: (a) applying a liquid to a skin surface; (b) allowing said liquid to harden; (c) removing said hardened liquid comprising a skin sample from said skin surface; (d) removing said skin sample from said hardened liquid; and (e) isolating RNA from said skin sample. 11. The method of claim 10, wherein said liquid is a sutureless wound closing agent. 12. The method of claim 10, wherein said skin sample is collected from a location on a patient selected from the group consisting of the upper back, mastoid process, hand, foot and deltoid. 13. The method of claim 10, further comprising quantifying said RNA. 14. The method of claim 13, wherein said RNA is quantified for the relative levels of transcripts for GAPDH, TNF.alpha., VEGF and K16. 15. The method of claim 12, wherein said locations include skin that is lesional and unaffected. 16. The method of claim 13, wherein said quantification is predictive of a patient's response to a drug. 17. The method of claim 16, wherein said patient has psoriasis and the drug is etanercept.

Details for Patent 8,389,215

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2027-07-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2027-07-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2027-07-26
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2027-07-26
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2027-07-26